NASH / MASH Clinical Trial Results

Browse clinical trials for NASH / MASH by phase, sponsor and reported results. Data from ClinicalTrials.gov.

• A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Sym
  Phase 2 · Akero Therapeutics, Inc · Completed · Jul 21, 2026
• Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrho
  Phase 2/3 · Galectin Therapeutics Inc. · Terminated · Jun 30, 2026
• Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease
  N/A · Wake Forest University Health Sciences · Completed · Jun 9, 2026
• Effect of Obesity on Proton Pump Inhibitors
  Phase 4 · Children's Mercy Hospital Kansas City · Completed · Jun 4, 2026
• Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MAS
  Phase 2 · Merck Sharp & Dohme LLC · Completed · Jun 1, 2026
• Phase 2a Study of HPG1860 in Subjects With NASH
  Phase 2 · Hepagene (Shanghai) Co., Ltd. · Completed · May 28, 2026
• Vitamin E Dosing Study
  Phase 2 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Completed · Mar 25, 2026
• Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
  Phase 1/2 · Stanford University · Completed · Mar 27, 2026
• A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
  Phase 1 · Eli Lilly and Company · Terminated · Apr 13, 2026
• A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
  Phase 3 · Galmed Research and Development, Ltd. · Suspended · Dec 16, 2024
• A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
  Phase 2 · Albireo · Completed · Sep 27, 2021
• Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study
  N/A · Philips Clinical & Medical Affairs Global · Completed · Jan 27, 2026
• Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
  N/A · Philips Clinical & Medical Affairs Global · Completed · Jan 23, 2026
• Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoh
  Phase 2 · 89bio, Inc. · Completed · Jan 6, 2026
• The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
  Phase 2 · Massachusetts General Hospital · Completed · Jan 6, 2026

Trials by condition

Lung CancerNon-Small Cell Lung CancerBreast CancerColorectal CancerGastric CancerLiver CancerPancreatic CancerProstate CancerOvarian CancerMelanomaLeukemiaLymphomaMultiple MyelomaGlioblastomaType 2 DiabetesObesityHypertensionHeart FailureAtrial FibrillationStrokeChronic Kidney DiseaseNASH / MASHAlzheimer’s DiseaseParkinson’s DiseaseMultiple SclerosisDepressionEpilepsyALSRheumatoid ArthritisPsoriasisAtopic DermatitisCrohn’s DiseaseUlcerative ColitisLupusAsthmaCOPD

All trials